Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Gains from Investment Securities (2018 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Gains from Investment Securities for 11 consecutive years, with $159000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Investment Securities rose 5200.0% year-over-year to $159000.0, compared with a TTM value of $359000.0 through Sep 2025, up 201.68%, and an annual FY2024 reading of $5.9 million, up 22.03% over the prior year.
  • Gains from Investment Securities was $159000.0 for Q3 2025 at Fennec Pharmaceuticals, up from $100000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $4.9 million in Q2 2023 and bottomed at $3000.0 in Q3 2024.
  • Average Gains from Investment Securities over 5 years is $1.4 million, with a median of $111500.0 recorded in 2024.
  • The sharpest move saw Gains from Investment Securities crashed 99.18% in 2022, then surged 12447.37% in 2024.
  • Year by year, Gains from Investment Securities stood at $3.7 million in 2021, then crashed by 98.14% to $68000.0 in 2022, then crashed by 48.53% to $35000.0 in 2023, then soared by 362.86% to $162000.0 in 2024, then dropped by 1.85% to $159000.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for FENC at $159000.0 in Q3 2025, $100000.0 in Q2 2025, and $123000.0 in Q1 2025.